Fredun [FREDUN] vs Aarti Drugs [AARTIDRUGS] Detailed Stock Comparison

Fredun

BSE
Loading...

Aarti Drugs

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Fredun wins in 9 metrics, Aarti Drugs wins in 11 metrics, with 0 ties. Aarti Drugs appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricFredunAarti DrugsBetter
P/E Ratio (TTM)27.5823.66Aarti Drugs
Price-to-Book Ratio4.133.26Aarti Drugs
Debt-to-Equity Ratio118.2244.92Aarti Drugs
PEG Ratio0.440.37Aarti Drugs
EV/EBITDA12.8517.07Fredun
Profit Margin (TTM)4.50%7.80%Aarti Drugs
Operating Margin (TTM)12.99%10.11%Fredun
EBITDA Margin (TTM)12.99%10.11%Fredun
Return on Equity13.96%12.28%Fredun
Return on Assets (TTM)4.05%6.53%Aarti Drugs
Free Cash Flow (TTM)$-351.69M$674.22MAarti Drugs
Dividend Yield0.09%0.22%Aarti Drugs
1-Year Return74.09%-4.79%Fredun
Price-to-Sales Ratio (TTM)1.261.84Fredun
Enterprise Value$7.89B$50.47BAarti Drugs
EV/Revenue Ratio1.592.08Fredun
Gross Profit Margin (TTM)26.88%36.77%Aarti Drugs
Revenue per Share (TTM)$1,128$265Fredun
Earnings per Share (Diluted)$48.08$20.63Fredun
Beta (Stock Volatility)0.860.12Aarti Drugs
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Fredun vs Aarti Drugs Stock Performance Analysis

Loading Price Chart...

Fredun
Aarti Drugs
Fredun Stock Overview | Aarti Drugs Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Fredun4.88%6.70%11.52%71.28%96.73%89.92%
Aarti Drugs0.73%4.61%0.24%1.59%41.06%7.93%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Fredun74.09%27.27%443.09%11,052.80%11,052.80%11,052.80%
Aarti Drugs-4.79%-0.89%-50.06%219.30%2,690.01%2,872.19%

News Based Sentiment: Fredun vs Aarti Drugs

Fredun

News based Sentiment: POSITIVE

Fredun Pharmaceuticals experienced a remarkably positive month, achieving a new 52-week high, strong financial growth, and a commitment to shareholder returns. While the planned equity issuance introduces some complexity, the overall narrative is one of significant growth and market outperformance, making it a noteworthy event for investors.

View Fredun News Sentiment Analysis

Aarti Drugs

News based Sentiment: POSITIVE

Aarti Drugs reported substantial profit growth in both Q1FY26 and FY2025, coupled with increased institutional interest from Mutual Funds. While shareholding changes and recent price volatility exist, the overall narrative points towards a strengthening investment case.

View Aarti Drugs News Sentiment Analysis

Performance & Financial Health Analysis: Fredun vs Aarti Drugs

MetricFREDUNAARTIDRUGS
Market Information
Market Cap i₹6.58B₹44.55B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i11,971201,942
90 Day Avg. Volume i16,431187,563
Last Close₹1,394.10₹491.60
52 Week Range₹635.00 - ₹1,395.65₹312.00 - ₹564.05
% from 52W High-0.11%-12.84%
All-Time High₹1,428.00 (Dec 05, 2022)₹1,026.95 (Oct 05, 2020)
% from All-Time High-2.37%-52.13%
Growth Metrics
Quarterly Revenue Growth0.52%0.06%
Quarterly Earnings Growth0.64%0.62%
Financial Health
Profit Margin (TTM) i0.05%0.08%
Operating Margin (TTM) i0.13%0.10%
Return on Equity (TTM) i0.14%0.12%
Debt to Equity (MRQ) i118.2244.92
Cash & Liquidity
Book Value per Share (MRQ)₹321.10₹149.84
Cash per Share (MRQ)₹12.65₹2.48
Operating Cash Flow (TTM) i₹-1,140,997,000₹2.83B
Levered Free Cash Flow (TTM) i₹197.39M₹1.68B
Dividends
Last 12-Month Dividend Yield i0.09%0.22%
Last 12-Month Dividend i₹0.70₹1.00

Valuation & Enterprise Metrics Analysis: Fredun vs Aarti Drugs

MetricFREDUNAARTIDRUGS
Price Ratios
P/E Ratio (TTM) i27.5823.66
Forward P/E iN/A15.02
PEG Ratio i0.440.37
Price to Sales (TTM) i1.261.84
Price to Book (MRQ) i4.133.26
Market Capitalization
Market Capitalization i₹6.58B₹44.55B
Enterprise Value i₹7.89B₹50.47B
Enterprise Value Metrics
Enterprise to Revenue i1.592.08
Enterprise to EBITDA i12.8517.07
Risk & Other Metrics
Beta i0.860.12
Book Value per Share (MRQ) i₹321.10₹149.84

Financial Statements Comparison: Fredun vs Aarti Drugs

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)FREDUNAARTIDRUGS
Revenue/Sales i₹1.19B₹5.91B
Cost of Goods Sold i₹873.04M₹3.73B
Gross Profit i₹320.99M₹2.17B
Research & Development i₹7.55MN/A
Operating Income (EBIT) i₹155.72M₹593.60M
EBITDA i₹169.91M₹743.90M
Pre-Tax Income i₹90.40M₹511.10M
Income Tax i₹22.75M₹-28.60M
Net Income (Profit) i₹67.66M₹539.70M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)FREDUNAARTIDRUGS
Cash & Equivalents i₹6.37M₹45.77M
Total Current Assets i₹4.28B₹13.38B
Total Current Liabilities i₹3.28B₹8.37B
Long-Term Debt i₹96.13M₹2.86B
Total Shareholders Equity i₹1.41B₹13.69B
Retained Earnings i₹628.39M₹12.40B
Property, Plant & Equipment i₹95.24M₹27.03M

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)FREDUNAARTIDRUGS
Operating Cash Flow iN/AN/A
Capital Expenditures iN/AN/A
Free Cash Flow iN/AN/A
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricFREDUNAARTIDRUGS
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Average Daily Volume (10 Day) i11,971201,942
Average Daily Volume (90 Day) i16,431187,563
Shares Outstanding i4.72M91.27M
Float Shares i2.72M39.04M
% Held by Insiders i0.59%0.60%
% Held by Institutions i0.00%0.11%

Dividend Analysis & Yield Comparison: Fredun vs Aarti Drugs

MetricFREDUNAARTIDRUGS
Last 12-Month Dividend i₹0.70₹1.00
Last 12-Month Dividend Yield i0.09%0.22%
3-Year Avg Annual Dividend i₹0.70₹1.00
3-Year Avg Dividend Yield i0.08%0.23%
3-Year Total Dividends i₹2.10₹3.00
Ex-Dividend DateSep 23, 2024Feb 04, 2025